These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 24881749)

  • 1. Neuroleptic malignant syndrome induced by combination therapy with tetrabenazine and tiapride in a Japanese patient with Huntington's disease at the terminal stage of recurrent breast cancer.
    Nozaki I; Furukawa Y; Kato-Motozaki Y; Ikeda T; Tagami A; Takahashi K; Ishida C; Komai K
    Intern Med; 2014; 53(11):1201-4. PubMed ID: 24881749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroleptic malignant syndrome related to tetrabenazine introduction and haloperidol discontinuation in Huntington's disease.
    Mateo D; Muñoz-Blanco JL; Giménez-Roldán S
    Clin Neuropharmacol; 1992 Feb; 15(1):63-8. PubMed ID: 1533561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders.
    Guay DR
    Am J Geriatr Pharmacother; 2010 Aug; 8(4):331-73. PubMed ID: 20869622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tetrabenazine as a cause of neuroleptic malignant syndrome.
    Ossemann M; Sindic CJ; Laterre C
    Mov Disord; 1996 Jan; 11(1):95. PubMed ID: 8771075
    [No Abstract]   [Full Text] [Related]  

  • 5. Tetrabenazine in the treatment of hyperkinetic movement disorders.
    Kenney C; Jankovic J
    Expert Rev Neurother; 2006 Jan; 6(1):7-17. PubMed ID: 16466307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroleptically induced dystonia in Huntington's disease: a case report.
    Schott K; Ried S; Stevens I; Dichgans J
    Eur Neurol; 1989; 29(1):39-40. PubMed ID: 2523309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroleptic malignant syndrome with aripiprazole in Huntington's disease.
    Gahr M; Orth M; Abler B
    Mov Disord; 2010 Oct; 25(14):2475-6. PubMed ID: 20669301
    [No Abstract]   [Full Text] [Related]  

  • 8. Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease.
    Burke RE; Fahn S; Mayeux R; Weinberg H; Louis K; Willner JH
    Neurology; 1981 Aug; 31(8):1022-5. PubMed ID: 6115336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroleptic Malignant Syndrome Induced by Olanzapine in a Patient with Huntington's Disease.
    Moreno JL; Palau Fayos JM; Díaz de Santiago A; García de Yébenes J
    J Huntingtons Dis; 2012; 1(1):31-2. PubMed ID: 25063189
    [No Abstract]   [Full Text] [Related]  

  • 10. Deutetrabenazine (Austedo) for Huntington's chorea and tardive dyskinesia.
    Med Lett Drugs Ther; 2018 Apr; 60(1545):65-68. PubMed ID: 29667946
    [No Abstract]   [Full Text] [Related]  

  • 11. Review of deutetrabenazine: a novel treatment for chorea associated with Huntington's disease.
    Dean M; Sung VW
    Drug Des Devel Ther; 2018; 12():313-319. PubMed ID: 29497277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Tetrabenazine (tetrabenazine Orphan) orally].
    J Pharm Belg; 2014 Dec; (4):49-50. PubMed ID: 25562927
    [No Abstract]   [Full Text] [Related]  

  • 13. Tardive Syndrome Associated With Tetrabenazine in Huntington Disease: A Case Report.
    Palermo G; Mazzucchi S; Unti E; Bonuccelli U; Ceravolo R
    J Clin Psychopharmacol; 2020; 40(6):628-630. PubMed ID: 33136925
    [No Abstract]   [Full Text] [Related]  

  • 14. [A study of neuroleptic malignant syndrome in the presenium and senium].
    Suzuki I; Honma H; Watanabe N; Matsubara S; Koyama T
    Seishin Shinkeigaku Zasshi; 1998; 100(6):387-97. PubMed ID: 9745353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroleptic malignant syndrome while on tiapride treatment.
    Duarte J; Campos JM; Cabezas C; Sagredo V; Cortina J; Clavería LE
    Clin Neuropharmacol; 1996 Dec; 19(6):539-40. PubMed ID: 8937795
    [No Abstract]   [Full Text] [Related]  

  • 16. Iatrogenic parkinsonism in Huntington's chorea.
    Moss JH; Stewart DE
    Can J Psychiatry; 1986 Dec; 31(9):865-6. PubMed ID: 2948633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deutetrabenazine for the treatment of Huntington's chorea.
    Bashir H; Jankovic J
    Expert Rev Neurother; 2018 Aug; 18(8):625-631. PubMed ID: 29996061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tetrabenazine and suicidal ideation.
    Shahani L
    J Neuropsychiatry Clin Neurosci; 2013; 25(1):E30. PubMed ID: 23487220
    [No Abstract]   [Full Text] [Related]  

  • 19. Deutetrabenazine: Treatment of hyperkinetic aspects of Huntington's disease, tardive dyskinesia and Tourette syndrome.
    Paton DM
    Drugs Today (Barc); 2017 Feb; 53(2):89-102. PubMed ID: 28387387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A case of tetrabenazine-induced neuroleptic malignant syndrome after prolonged treatment.
    Petzinger GM; Bressman SB
    Mov Disord; 1997 Mar; 12(2):246-8. PubMed ID: 9087987
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.